Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/212408
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.author | Picornell, A. C. | es_ES |
dc.contributor.author | Echevarria, I. | es_ES |
dc.contributor.author | Álvarez, E. | es_ES |
dc.contributor.author | López-Tarruella, S. | es_ES |
dc.contributor.author | Jerez, Y. | es_ES |
dc.contributor.author | Hoadley, K. | es_ES |
dc.contributor.author | Parker, J. S. | es_ES |
dc.contributor.author | Monte-Millán, M. del | es_ES |
dc.contributor.author | Ramos-Medina, R. | es_ES |
dc.contributor.author | Gayarre, Javier | es_ES |
dc.contributor.author | Ocaña, I. | es_ES |
dc.contributor.author | Cebollero, M. | es_ES |
dc.contributor.author | Massarrah, T. | es_ES |
dc.contributor.author | Moreno, Fernando | es_ES |
dc.contributor.author | García‐Sáenz, José Ángel | es_ES |
dc.contributor.author | Gómez Moreno, H. | es_ES |
dc.contributor.author | Ballesteros, A. | es_ES |
dc.contributor.author | Ruiz-Borrego, Manuel | es_ES |
dc.contributor.author | Perou, C. M. | es_ES |
dc.contributor.author | Martín, M. | es_ES |
dc.date.accessioned | 2020-05-28T07:39:34Z | - |
dc.date.available | 2020-05-28T07:39:34Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | BMC Genomics 20: 452 (2019) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10261/212408 | - |
dc.description.abstract | [Background]: Full RNA-Seq is a fundamental research tool for whole transcriptome analysis. However, it is too costly and time consuming to be used in routine clinical practice. We evaluated the transcript quantification agreement between RNA-Seq and a digital multiplexed gene expression platform, and the subtype call after running the PAM50 assay in a series of breast cancer patients classified as triple negative by IHC/FISH. The goal of this study is to analyze the concordance between both expression platforms overall, and for calling PAM50 triple negative breast cancer intrinsic subtypes in particular. | es_ES |
dc.description.abstract | [Results]: The analyses were performed in paraffin-embedded tissues from 96 patients recruited in a multicenter, prospective, non-randomized neoadjuvant triple negative breast cancer trial (NCT01560663). Pre-treatment core biopsies were obtained following clinical practice guidelines and conserved as FFPE for further RNA extraction. PAM50 was performed on both digital multiplexed gene expression and RNA-Seq platforms. Subtype assignment was based on the nearest centroid classification following this procedure for both platforms and it was concordant on 96% of the cases (N = 96). In four cases, digital multiplexed gene expression analysis and RNA-Seq were discordant. The Spearman correlation to each of the centroids and the risk of recurrence were above 0.89 in both platforms while the agreement on Proliferation Score reached up to 0.97. In addition, 82% of the individual PAM50 genes showed a correlation coefficient > 0.80. | es_ES |
dc.description.abstract | [Conclusions]: In our analysis, the subtype calling in most of the samples was concordant in both platforms and the potential discordances had reduced clinical implications in terms of prognosis. If speed and cost are the main driving forces then the preferred technique is the digital multiplexed platform, while if whole genome patterns and subtype are the driving forces, then RNA-Seq is the preferred method. | es_ES |
dc.description.sponsorship | M.M was supported by two research grants from Ministry of Economy and Competitiveness ISCIII-FIS grants (PI 12/02684): “Predictores genómicos de respuesta a la quimioterapia neoadyuvante con docetaxel-carboplatino en pacientes con cáncer de mama triple negativo”/“Genomic predictors of response to neoadjuvant chemotherapy with docetaxel-carboplatin in patients with triple negative breast cancer”; and (PI 15/00117): “Cáncer de mama triple negative: Predicción de respuesta a docetaxel-carboplatino neoadyuvante mediante caracterización de TILs y firmas inmunes basadas en secuenciación masiva de RNA”/” Triple negative breast cancer: Prediction of response to neoadjuvant docetaxel-carboplatin by characterization of TILs and immune signatures based on massive RNA sequencing”. C.M.P was supported by funds from the NCI Breast SPORE program (P50-CA58223). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | BioMed Central | es_ES |
dc.relation.isversionof | Publisher's version | es_ES |
dc.rights | openAccess | es_ES |
dc.subject | PAM50 | es_ES |
dc.subject | Breast cancer | es_ES |
dc.subject | Triple negative breast cancer | es_ES |
dc.subject | RNA-Seq | es_ES |
dc.subject | Multiplexed gene expression | es_ES |
dc.title | Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series | es_ES |
dc.type | artículo | es_ES |
dc.identifier.doi | 10.1186/s12864-019-5849-0 | - |
dc.description.peerreviewed | Peer reviewed | es_ES |
dc.relation.publisherversion | https://doi.org/10.1186/s12864-019-5849-0 | es_ES |
dc.identifier.e-issn | 1471-2164 | - |
dc.rights.license | http://creativecommons.org/licenses/by/4.0/ | es_ES |
dc.contributor.funder | Ministerio de Economía y Competitividad (España) | es_ES |
dc.contributor.funder | European Commission | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.relation.csic | Sí | es_ES |
oprm.item.hasRevision | no ko 0 false | * |
dc.identifier.funder | http://dx.doi.org/10.13039/501100000780 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100004587 | es_ES |
dc.identifier.funder | http://dx.doi.org/10.13039/501100003329 | es_ES |
dc.identifier.pmid | 31159741 | - |
dc.type.coar | http://purl.org/coar/resource_type/c_6501 | es_ES |
item.openairetype | artículo | - |
item.grantfulltext | open | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | With Fulltext | - |
item.languageiso639-1 | en | - |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
breaserie.pdf | 1,83 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
24
checked on 19-abr-2024
SCOPUSTM
Citations
29
checked on 15-abr-2024
WEB OF SCIENCETM
Citations
27
checked on 28-feb-2024
Page view(s)
185
checked on 18-abr-2024
Download(s)
106
checked on 18-abr-2024